Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era

Blood Reviews
L A ButlerJ F Seymour

Abstract

The anti-CD20 antibodies represent a major advancement in the therapeutic options available for chronic lymphocytic leukemia. The addition of rituximab, ofatumumab and obinutuzumab to various chemotherapy regimens has led to considerable improvements in both response and survival. Ocaratuzumab, veltuzumab and ublituximab are currently being explored within the trial setting. We review the current status of these antibodies, and discuss how their mechanisms of action may impact on the choice of combinations with novel small molecule agents.

Citations

Jun 20, 2018·Frontiers in Oncology·Timothy M PierpontKristy L Richards
Jul 12, 2019·Frontiers in Immunology·Dario DidonaMichael Hertl
Nov 15, 2019·HemaSphere·Deyan Y YosifovDaniel Mertens
Jun 12, 2020·Der Nervenarzt·Jonas GrafHans-Peter Hartung
Oct 14, 2020·Immunotherapy·Gérôme BohelayPhilippe Musette
May 1, 2021·Blood Cancer Journal·Natalia Timofeeva, Varsha Gandhi

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.